{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:59:49Z","timestamp":1787507989793,"version":"build-2736575974"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["173338,2020"],"award-info":[{"award-number":["173338,2020"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["153081,2017"],"award-info":[{"award-number":["153081,2017"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["144159,2016"],"award-info":[{"award-number":["144159,2016"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004376","name":"Terry Fox Research Institute","doi-asserted-by":"publisher","award":["1062"],"award-info":[{"award-number":["1062"]}],"id":[{"id":"10.13039\/501100004376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004489","name":"Mitacs","doi-asserted-by":"publisher","award":["IT1055"],"award-info":[{"award-number":["IT1055"]}],"id":[{"id":"10.13039\/501100004489","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004489","name":"Mitacs","doi-asserted-by":"publisher","award":["IT1238"],"award-info":[{"award-number":["IT1238"]}],"id":[{"id":"10.13039\/501100004489","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004489","name":"Mitacs","doi-asserted-by":"publisher","award":["IT1495"],"award-info":[{"award-number":["IT1495"]}],"id":[{"id":"10.13039\/501100004489","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.canlet.2021.11.004","type":"journal-article","created":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T13:02:19Z","timestamp":1636462939000},"page":"160-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Patient-derived xenograft models of neuroendocrine prostate cancer"],"prefix":"10.1016","volume":"525","author":[{"given":"Mingchen","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8731-0156","authenticated-orcid":false,"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9749-8591","authenticated-orcid":false,"given":"Yuzhuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2021.11.004_bib1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/j.seminoncol.2006.10.026","article-title":"Unusual and underappreciated: small cell carcinoma of the prostate","volume":"34","author":"Palmgren","year":"2007","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.canlet.2021.11.004_bib2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41585-021-00490-0","article-title":"Molecular events in neuroendocrine prostate cancer development","volume":"18","author":"Wang","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.canlet.2021.11.004_bib3","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2013.54.3553","article-title":"Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis","volume":"32","author":"Wang","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2021.11.004_bib4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1677\/ERC-07-0061","article-title":"Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells","volume":"14","author":"Yuan","year":"2007","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2021.11.004_bib5","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1158\/1078-0432.CCR-13-3309","article-title":"Aggressive variants of castration-resistant prostate cancer","volume":"20","author":"Beltran","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2021.11.004_bib6","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1210\/me.2003-0031","article-title":"Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells","volume":"17","author":"Wright","year":"2003","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.canlet.2021.11.004_bib7","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","article-title":"The role of lineage plasticity in prostate cancer therapy resistance","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2021.11.004_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","article-title":"Clinical features of neuroendocrine prostate cancer","volume":"121","author":"Conteduca","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2021.11.004_bib9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","article-title":"Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets","volume":"1","author":"Beltran","year":"2011","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2021.11.004_bib10","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1200\/JCO.2011.41.5166","article-title":"Challenges in recognizing treatment-related neuroendocrine prostate cancer","volume":"30","author":"Beltran","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2021.11.004_bib11","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2014.57.5100","article-title":"Neuroendocrine prostate cancer after hormonal therapy: knowing is half the battle","volume":"32","author":"Tagawa","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2021.11.004_bib12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrurol.2014.21","article-title":"Small cell carcinoma of the prostate","volume":"11","author":"Nadal","year":"2014","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.canlet.2021.11.004_bib13","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1200\/JCO.2002.12.065","article-title":"Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate","volume":"20","author":"Papandreou","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2021.11.004_bib14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/iju.13526","article-title":"Clinical and molecular features of treatment-related neuroendocrine prostate cancer","volume":"25","author":"Akamatsu","year":"2018","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.canlet.2021.11.004_bib15","first-page":"2913","article-title":"Establishment and identification of small cell lung cancer cell lines having classic and variant features","volume":"45","author":"Carney","year":"1985","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2021.11.004_bib16","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1593\/neo.07103","article-title":"Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model","volume":"9","author":"Mertz","year":"2007","journal-title":"Neoplasia"},{"key":"10.1016\/j.canlet.2021.11.004_bib17","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1111\/cas.14935","article-title":"Establishment and characterization of a novel treatment-related neuroendocrine prostate cancer cell line KUCaP13","volume":"112","author":"Okasho","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2021.11.004_bib18","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ccell.2016.03.001","article-title":"N-myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cells","volume":"29","author":"Lee","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2021.11.004_bib19","doi-asserted-by":"crossref","first-page":"E4473","DOI":"10.1073\/pnas.1802354115","article-title":"Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer","volume":"115","author":"Lee","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2021.11.004_bib20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/sj.pcan.4500296","article-title":"Pathologic progression of autochthonous prostate cancer in the TRAMP model","volume":"2","author":"Gingrich","year":"1999","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.canlet.2021.11.004_bib21","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1073\/pnas.92.8.3439","article-title":"Prostate cancer in a transgenic mouse","volume":"92","author":"Greenberg","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2021.11.004_bib22","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1158\/2159-8290.CD-16-1174","article-title":"Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer","volume":"7","author":"Zou","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2021.11.004_bib23","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ccell.2016.09.005","article-title":"N-myc induces an EZH2-mediated transcriptional Program driving neuroendocrine prostate cancer","volume":"30","author":"Dardenne","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2021.11.004_bib24","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.canlet.2021.11.004_bib25","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/PAS.0000000000000208","article-title":"Proposed morphologic classification of prostate cancer with neuroendocrine differentiation","volume":"38","author":"Epstein","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.canlet.2021.11.004_bib26","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2021.11.004_bib27","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/path.4047","article-title":"From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer","volume":"227","author":"Lapuk","year":"2012","journal-title":"J. Pathol."},{"key":"10.1016\/j.canlet.2021.11.004_bib28","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","article-title":"Patient-derived xenograft models: an emerging platform for translational cancer research","volume":"4","author":"Hidalgo","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2021.11.004_bib29","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13045-017-0470-7","article-title":"Current status and perspectives of patient-derived xenograft models in cancer research","volume":"10","author":"Lai","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2021.11.004_bib30","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nprot.2007.25","article-title":"Establishment of human tumor xenografts in immunodeficient mice","volume":"2","author":"Morton","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.canlet.2021.11.004_bib31","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030536","article-title":"Preclinical models of prostate cancer: patient-derived xenografts, organoids, and other explant models","volume":"8","author":"Risbridger","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.canlet.2021.11.004_bib32","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrurol.2017.19","article-title":"Patient-derived xenografts as in vivo models for research in urological malignancies","volume":"14","author":"Inoue","year":"2017","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.canlet.2021.11.004_bib33","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/pros.23701","article-title":"Movember GAP1 PDX project: an international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models","volume":"78","author":"Navone","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2021.11.004_bib34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.mce.2017.03.013","article-title":"Patient-derived xenografts: a platform for accelerating translational research in prostate cancer","volume":"462","author":"Davies","year":"2018","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.canlet.2021.11.004_bib35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bcp.2014.06.008","article-title":"Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology","volume":"91","author":"Rosfjord","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.canlet.2021.11.004_bib36","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrclinonc.2012.61","article-title":"Patient-derived tumour xenografts as models for oncology drug development","volume":"9","author":"Tentler","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2021.11.004_bib37","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1158\/0008-5472.CAN-13-2921-T","article-title":"High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development","volume":"74","author":"Lin","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2021.11.004_bib38","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/pros.23313","article-title":"LuCaP prostate cancer patient-derived xenografts reflect the molecular heterogeneity of advanced disease an--d serve as models for evaluating cancer therapeutics","volume":"77","author":"Nguyen","year":"2017","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2021.11.004_bib39","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.celrep.2015.07.012","article-title":"The placental gene PEG10 promotes progression of neuroendocrine prostate cancer","volume":"12","author":"Akamatsu","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2021.11.004_bib40","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1158\/1078-0432.CCR-20-0479","article-title":"The MD anderson prostate cancer patient-derived xenograft series (MDA PCa PDX) captures the molecular landscape of prostate cancer and facilitates marker-driven therapy development","volume":"26","author":"Palanisamy","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2021.11.004_bib41","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1172\/JCI128212","article-title":"Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer","volume":"129","author":"Labrecque","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2021.11.004_bib42","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1038\/s41467-021-25175-5","article-title":"The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology","volume":"12","author":"Risbridger","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2021.11.004_bib43","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaa132","article-title":"Moving beyond drug screening to versatile models for research discovery","volume":"4","author":"Risbridger","year":"2020","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.canlet.2021.11.004_bib44","article-title":"Proteogenomic integration reveals therapeutic targets in breast cancer xenografts","volume":"8","author":"Huang","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2021.11.004_bib45","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1158\/1078-0432.CCR-18-0729","article-title":"Proteogenomic characterization of patient-derived xenografts highlights the role of REST in neuroendocrine differentiation of castration-resistant prostate cancer","volume":"25","author":"Flores-Morales","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2021.11.004_bib46","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1093\/annonc\/mdx416","article-title":"Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors","volume":"28","author":"Izumchenko","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2021.11.004_bib47","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1158\/0008-5472.CAN-19-0349","article-title":"Integrative pharmacogenomics analysis of patient-derived xenografts","volume":"79","author":"Mer","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2021.11.004_bib48","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s12859-020-03633-z","article-title":"PDXGEM: patient-derived tumor xenograft-based gene expression model for predicting clinical response to anticancer therapy in cancer patients","volume":"21","author":"Kim","year":"2020","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.canlet.2021.11.004_bib49","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jgg.2021.03.007","article-title":"Large-scale pharmacogenomic studies and drug response prediction for personalized cancer medicine","volume":"48","author":"Feng","year":"2021","journal-title":"J Genet Genomics"},{"key":"10.1016\/j.canlet.2021.11.004_bib50","doi-asserted-by":"crossref","first-page":"16059","DOI":"10.18632\/oncotarget.3863","article-title":"Correlation between tumor engraftment in patient-derived xenograft models and clinical outcomes in colorectal cancer patients","volume":"6","author":"Oh","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2021.11.004_bib51","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/pros.21301","article-title":"Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles","volume":"71","author":"Aparicio","year":"2011","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2021.11.004_bib52","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.eururo.2018.06.020","article-title":"Patient-derived models of abiraterone- and enzalutamide-resistant prostate cancer reveal sensitivity to ribosome-directed therapy","volume":"74","author":"Lawrence","year":"2018","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2021.11.004_bib53","first-page":"1055","article-title":"Development of seven new human prostate tumor xenograft models and their histopathological characterization","volume":"149","author":"van Weerden","year":"1996","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2021.11.004_bib54","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/pros.2990110307","article-title":"Xenografted small cell undifferentiated cancer of prostate: possible common origin with prostatic adenocarcinoma","volume":"11","author":"van Haaften-Day","year":"1987","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2021.11.004_bib55","first-page":"6563","article-title":"A unique xenograft model of human prostatic small cell carcinoma","volume":"60","author":"Pinthus","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2021.11.004_bib56","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13148-015-0074-4","article-title":"Polycomb-mediated silencing in neuroendocrine prostate cancer","volume":"7","author":"Clermont","year":"2015","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.canlet.2021.11.004_bib57","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-15-1259","article-title":"Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers","volume":"22","author":"Aparicio","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2021.11.004_bib58","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1158\/1078-0432.CCR-11-1867","article-title":"Modeling a lethal prostate cancer variant with small-cell carcinoma features","volume":"18","author":"Tzelepi","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2021.11.004_bib59","first-page":"2720","article-title":"Frequent inactivation of PTEN in prostate cancer cell lines and xenografts","volume":"58","author":"Vlietstra","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2021.11.004_bib60","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0090-4295(97)00684-5","article-title":"Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment","volume":"51","author":"Jiborn","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.canlet.2021.11.004_bib61","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/pros.20225","article-title":"Development and characterization of efficient xenograft models for benign and malignant human prostate tissue","volume":"64","author":"Wang","year":"2005","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2021.11.004_bib62","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.diff.2015.10.012","article-title":"Subrenal capsule grafting technology in human cancer modeling and translational cancer research","volume":"91","author":"Wang","year":"2016","journal-title":"Differentiation"},{"key":"10.1016\/j.canlet.2021.11.004_bib63","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2021.11.004_bib64","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fonc.2018.00069","article-title":"Function of tumor suppressors in resistance to antiandrogen therapy and luminal epithelial plasticity of aggressive variant neuroendocrine prostate cancers","volume":"8","author":"Soundararajan","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.canlet.2021.11.004_bib65","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/modpathol.2017.44","article-title":"FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate","volume":"30","author":"Park","year":"2017","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.canlet.2021.11.004_bib66","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-15-1263","article-title":"The master neural transcription factor BRN2 is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer","volume":"7","author":"Bishop","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2021.11.004_bib67","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aah4307","article-title":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer","volume":"355","author":"Mu","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.canlet.2021.11.004_bib68","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/nar\/gkt921","article-title":"REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer","volume":"42","author":"Svensson","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2021.11.004_bib69","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/jamaoncol.2015.1313","article-title":"Whole-exome sequencing of metastatic cancer and biomarkers of treatment response","volume":"1","author":"Beltran","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.canlet.2021.11.004_bib70","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0002-9440(10)64226-5","article-title":"A neuroendocrine\/small cell prostate carcinoma xenograft-LuCaP 49","volume":"161","author":"True","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2021.11.004_bib71","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0303-7207(88)90131-1","article-title":"Ectopic hormone production by a prostatic small cell carcinoma xenograft line","volume":"55","author":"Jelbart","year":"1988","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.canlet.2021.11.004_bib72","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/pros.20702","article-title":"Irradiation enhances the metastatic potential of prostatic small cell carcinoma xenografts","volume":"68","author":"Agemy","year":"2008","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2021.11.004_bib73","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.18632\/oncotarget.2809","article-title":"Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer","volume":"6","author":"Lin","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2021.11.004_bib74","doi-asserted-by":"crossref","DOI":"10.1093\/gigascience\/giy050","article-title":"The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications","volume":"7","author":"Ramnarine","year":"2018","journal-title":"GigaScience"},{"key":"10.1016\/j.canlet.2021.11.004_bib75","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41467-018-08133-6","article-title":"ONECUT2 is a driver of neuroendocrine prostate cancer","volume":"10","author":"Guo","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2021.11.004_bib76","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1158\/0008-5472.CAN-17-3677","article-title":"Heterochromatin protein 1alpha mediates development and aggressiveness of neuroendocrine prostate cancer","volume":"78","author":"Ci","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2021.11.004_bib77","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2217\/epi.16.6","article-title":"The role of epigenetics and long noncoding RNA MIAT in neuroendocrine prostate cancer","volume":"8","author":"Crea","year":"2016","journal-title":"Epigenomics"},{"key":"10.1016\/j.canlet.2021.11.004_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21031078","article-title":"Gene expression signature predictive of neuroendocrine transformation in prostate adenocarcinoma","volume":"21","author":"Ostano","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2021.11.004_bib79","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1002\/1878-0261.12954","article-title":"The evolutionarily conserved long non-coding RNA LINC00261 drives neuroendocrine prostate cancer proliferation and metastasis via distinct nuclear and cytoplasmic mechanisms","volume":"15","author":"Mather","year":"2021","journal-title":"Mol Oncol"},{"key":"10.1016\/j.canlet.2021.11.004_bib80","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ebiom.2018.08.011","article-title":"A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network","volume":"35","author":"Lee","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.canlet.2021.11.004_bib81","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1172\/JCI135373","article-title":"LIN28B promotes the development of neuroendocrine prostate cancer","volume":"130","author":"Lovnicki","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2021.11.004_bib82","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40610-018-0095-9","article-title":"Epigenetic regulation in prostate cancer progression","volume":"4","author":"Ruggero","year":"2018","journal-title":"Curr Mol Biol Rep"},{"key":"10.1016\/j.canlet.2021.11.004_bib83","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1080\/15592294.2016.1146851","article-title":"Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas","volume":"11","author":"Kleb","year":"2016","journal-title":"Epigenetics"},{"key":"10.1016\/j.canlet.2021.11.004_bib84","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Mohler","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.canlet.2021.11.004_bib85","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/nm.3954","article-title":"High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response","volume":"21","author":"Gao","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2021.11.004_bib86","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nm.2323","article-title":"Cancer genomics: from discovery science to personalized medicine","volume":"17","author":"Chin","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2021.11.004_bib87","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/1078-0432.CCR-17-1872","article-title":"Targeting the MYCN-PARP-DNA damage response pathway in neuroendocrine prostate cancer","volume":"24","author":"Zhang","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2021.11.004_bib88","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1158\/1078-0432.CCR-19-0317","article-title":"PARP inhibition suppresses GR-MYCN-CDK5-RB1-E2F1 signaling and neuroendocrine differentiation in castration-resistant prostate cancer","volume":"25","author":"Liu","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2021.11.004_bib89","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bcp.2018.11.014","article-title":"Ribosome biogenesis: an emerging druggable pathway for cancer therapeutics","volume":"159","author":"Catez","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.canlet.2021.11.004_bib90","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1158\/1078-0432.CCR-18-0409","article-title":"A PDX\/organoid biobank of advanced prostate cancers captures genomic and phenotypic heterogeneity for disease modeling and therapeutic screening","volume":"24","author":"Beshiri","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2021.11.004_bib91","doi-asserted-by":"crossref","DOI":"10.3390\/cells9061398","article-title":"Conditionally reprogrammed cells from patient-derived xenograft to model neuroendocrine prostate cancer development","volume":"9","author":"Ci","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2021.11.004_bib92","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1530\/ERC-11-0368","article-title":"Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway","volume":"19","author":"Chen","year":"2012","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2021.11.004_bib93","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/onc.2015.94","article-title":"XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer","volume":"35","author":"Morton","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2021.11.004_bib94","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nbt.2858","article-title":"Development and function of human innate immune cells in a humanized mouse model","volume":"32","author":"Rongvaux","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2021.11.004_bib95","series-title":"Patient-Derived Xenograft Models of Human Cancer","year":"2017"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352100570X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352100570X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:52:51Z","timestamp":1778683971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030438352100570X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":95,"alternative-id":["S030438352100570X"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2021.11.004","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-derived xenograft models of neuroendocrine prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2021.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}